Sophia Genetics

SOPHiA GENETICS technology will help increase cancer research abilities BOSTON and LAUSANNE, Switzerland, May 16, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Natural State Laboratories, a private, full-service, state-of-the-art molecular laboratory based in Little Rock, Arkansas, has chosen SOPHiA GENETICS …

Natural State Laboratories Chooses SOPHiA GENETICS to Help Launch their In-House Hereditary Cancer Testing Read More »

In just one year of using SOPHiA DDM™ HRD, Dasa reaches 2,000 samples analyzed  BOSTON and LAUSANNE, Switzerland, May 8, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, celebrates today with longstanding partner, Dasa, the largest integrated healthcare network in Brazil, as it reaches a milestone of 2,000 …

Dasa Expands Its Capabilities with SOPHiA GENETICS Read More »

Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company SOPHiA GENETICS’ next-generation solution CarePath, fueled by current real world observational data, was previewed for attendees BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (PR NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a …

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event Read More »

BOSTON and LAUSANNE, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today Chief Executive Officer, Dr. Jurgi Camblong and Chief Financial Officer, Ross Muken will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, …

SOPHiA GENETICS to Participate in Fireside Chat at 20th Annual Morgan Stanley Global Healthcare Conference Read More »

Steady Operational Performance Amidst Macroeconomic Headwinds BOSTON and LAUSANNE, Switzerland, Aug. 09, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the second quarter ended June 30, 2022. READ MORE  

BOSTON and LAUSANNE, Switzerland, Aug. 04, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today it will host its first-ever Investor Day on Tuesday, September 20, 2022, at PUBLIC Hotel in New York City. The event will begin at 1:30 p.m. EDT and is expected …

SOPHiA GENETICS to Host Investor Day on September 20, 2022, in New York City Read More »

BOSTON, United States and LAUSANNE, Switzerland, June 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company”), today announced that the Company has published its first Environmental, Social and Governance Impact Summary (“ESG Impact Summary”). The ESG Impact Summary highlights the Company’s policies, ongoing practices, and recent initiatives across a range of areas including innovation and …

SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2022 on August 9, 2022 Read More »

BOSTON, United States and LAUSANNE, Switzerland, June 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company”), today announced that the Company has published its first Environmental, Social and Governance Impact Summary (“ESG Impact Summary”). The ESG Impact Summary highlights the Company’s policies, ongoing practices, and recent initiatives across a range of areas including innovation and …

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary Read More »

BOSTON, United States and LAUSANNE, Switzerland, June 9, 2022 — SOPHiA GENETICS (Nasdaq: SOPH), the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to …

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS Read More »

Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer Nearly 20 participating sites activated worldwide with over 500 patients recruited to date. Early findings conceptually validate the potential for multimodal signatures to …

SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022 Read More »